Etelcalcetide Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 2.5 mg/mL, 5 mg/mL, 10 mg/mL
Reference Brands: Parsabiv (USA/EU)
Category:
Critical Care
Etelcalcetide is available in Injection
and strengths such as 2.5 mg/mL, 5 mg/mL, 10 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Etelcalcetide is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Etelcalcetide can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Etelcalcetide is a synthetic peptide calcimimetic and calcium-sensing receptor (CaSR) agonist used for the treatment of secondary hyperparathyroidism (sHPT) in adults with chronic kidney disease (CKD) on hemodialysis. Composed of seven D-amino acids, etelcalcetide is administered intravenously and functions by mimicking calcium to allosterically activate the CaSR expressed on parathyroid cells. Activation of this receptor suppresses the synthesis and secretion of parathyroid hormone (PTH), helping to reduce elevated PTH levels commonly observed in patients with CKD.
By lowering PTH, etelcalcetide also contributes to the regulation of serum calcium and phosphorus levels, addressing the imbalances in calcium-phosphate homeostasis that can occur in chronic kidney disease. Its targeted mechanism provides effective management of sHPT, which is associated with bone and cardiovascular complications in CKD patients.
Etelcalcetide is marketed under the brand name Parsabiv and is delivered via pre-filled intravenous vials for use during hemodialysis sessions. It represents an important therapeutic option for controlling PTH and mineral metabolism, improving patient outcomes, and reducing the risks associated with chronic elevations of parathyroid hormone in the CKD population.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing